Lin, Meisi et al. published their research in Medicine (Philadelphia, PA, United States) in 2020 | CAS: 117976-90-6

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.COA of Formula: C18H20N3NaO3S

Therapeutic efficacy and safety of Kangfuxin in combination with rabeprazole in the treatment of peptic ulcer: A systematic review and meta-analysis was written by Lin, Meisi;Zhang, Siyuan;Zhang, Minyue;Shi, Jinfeng;Zhang, Chen;Luo, Ruifeng;You, Jieshu;Sun, Jiayi;Zhang, Jinming;Gao, Fei. And the article was included in Medicine (Philadelphia, PA, United States) in 2020.COA of Formula: C18H20N3NaO3S The following contents are mentioned in the article:

Meta-anal. of Kangfuxin (KFX), a well-known Chinese patent medicine which extracted from Periplaneta americana, is widely used as an adjuvant in the treatment of peptic ulcers (PUs) with proton pump inhibitors (PPIs) such as rabeprazole, in China. However, no clear consensus has been reached on the efficacy for PU treatment. We searched in 7 electronic databases to find randomized controlled trials (RCTs) completed before May 31, 2020 to explore the clin. efficiency of KFX plus rabeprazole in the treatment of PU. Risk ratio (RR) corresponding to 95% confidence interval (CI) was calculated to estimate the outcomes. Publication bias was assessed by both Egger’s and Begg’s tests. Statistical analyses were performed using RevMan 5.4 and Stata version 10.0. Twenty-five RCTs, comprising 2555 PU patients, were included in this study. Meta-anal. showed that, when compared with rabeprazole-based treatment alone, KFX plus rabeprazole significantly improved the healing rate (RR=1.34, 95% CI 1.25-1.44) and overall response rate of ulcers (RR=1.16, 95% CI 1.13-1.20), alleviated the clin. symptoms of PU (RR=1.14, 95% CI 1.08-1.21), and reduced the recurrence of PU (RR=0.38, 95% CI 0.24-0.61) without an increase in the occurrence of adverse events (RR=0.92, 95% CI 0.66-1.28). Our study suggests that KFX combined with rabeprazole showed pos. therapeutic effects and is safe for treating PU, which may provide more reliable evidence for the clin. use of KFX in the treatment of PU. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6COA of Formula: C18H20N3NaO3S).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.COA of Formula: C18H20N3NaO3S

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem